IFN-β and multiple sclerosis: from etiology to therapy and back.

@article{Annibali2015IFNAM,
  title={IFN-β and multiple sclerosis: from etiology to therapy and back.},
  author={Viviana Annibali and Rosella Mechelli and Silvia Zuleta Romano and Maria Chiara Buscarinu and Arianna Fornasiero and Renato Umeton and Vito A. G. Ricigliano and Francesco Orzi and Eliana M Coccia and Marco Salvetti and Giovanni Alberto Ristori},
  journal={Cytokine & growth factor reviews},
  year={2015},
  volume={26 2},
  pages={
          221-8
        }
}
Several immunomodulatory treatments are currently available for relapsing-remitting forms of multiple sclerosis (RRMS). Interferon beta (IFN) was the first therapeutic intervention able to modify the course of the disease and it is still the most used first-line treatment in RRMS. Though two decades have passed since IFN-β was introduced in the management of MS, it remains a valid approach because of its good benefit/risk profile. This is witnessed by new efforts of pharmaceutical industry to… CONTINUE READING
BETA

Similar Papers

Tables and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis

  • Therapeutics and clinical risk management
  • 2015
VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Multiple sclerosis: an example of pathogenic viral interaction?

  • Virology Journal
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 88 REFERENCES

International Multiple Sclerosis

Consortium, AH Beecham, +3 authors A Kemppinen
  • Nat Genet
  • 2013
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

A weak signal for strong responses: interferon-alpha/beta revisited

  • Nature Reviews Molecular Cell Biology
  • 2001
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL